Vasculitis Clinical Trial
Official title:
A Randomized Trial Comparing Methotrexate Versus Mycophenolate Mofetil for Remission Maintenance in Wegener's Granulomatosis and Related Vasculitides
This study will compare the safety and effectiveness of two drugs-methotrexate and
mycophenolate mofetil (MPM)-in preventing disease recurrence in patients with Wegener's
granulomatosis and related inflammatory blood vessel disorders. The standard treatment for
these conditions is combination drug therapy with prednisone plus cyclophosphamide. However,
although most patients improve on this therapy and achieve disease remission, many
experience a relapse (return of the disease) some time after therapy is stopped. Also, these
drugs can produce serious side effects during treatment. This study will test a new
treatment regimen to try to maintain disease remission in these patients with minimal side
effects.
Patients with Wegener's granulomatosis or other related blood vessel disorders between 10
and 80 years old will be considered for this study. All participants will start therapy with
daily doses of prednisone and cyclophosphamide. Prednisone will be reduced gradually and
then stopped after symptoms improve significantly. Cyclophosphamide will continue until the
disease is in remission. Patients in remission will then be randomly assigned to continue
treatment with either MPM or methotrexate. MPM is taken twice a day by mouth. Methotrexate
is taken once a week, usually by mouth, but in some cases, by injection into a muscle or
under the skin. Patients who do well and have no side effects will continue treatment for 2
years. Then, the drug will gradually be reduced (usually at monthly intervals) and finally
stopped. No further treatment will be given unless a relapse occurs. At that time, the type
of treatment will depend on various medical factors, including the severity of the
recurrence and the patient's history of drug side effects.
Physical examinations and various tests, including blood and urine analyses, and X-rays,
will be done periodically to evaluate the response to treatment and monitor drug side
effects. The total duration of the study-from the screening evaluation through a 2-year
follow up after all medications have been stopped-is about 5 to 6 years.
Status | Completed |
Enrollment | 75 |
Est. completion date | June 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: 1. Documentation of Wegener's granulomatosis (WG) or a related systemic vasculitis based on clinical characteristics and histopathologic and/or angiographic evidence of vasculitis. In the absence of histopathologic and/or angiographic evidence of vasculitis, patients who meet one of the following criteria and in whom infectious and autoimmune diseases that may mimic WG or a related systemic vasculitides have been excluded will also be eligible: A. A positive assay for anti-neutrophil cytoplasmic autoantibodies (C- or P-ANCA) and the presence of glomerulonephritis defined by red blood cell casts and proteinuria or renal biopsy showing necrotizing glomerulonephritis in the absence of immune deposits. B. A positive assay for anti-neutrophil cytoplasmic autoantibodies (C- or P-ANCA) and the presence of granulomatous inflammation on biopsy plus abnormal chest radiograph (defined as the presence of nodules, fixed infiltrates, or cavities) plus nasal/oral inflammation on clinical examination. 2. Age 10-80 years. 3. Evidence of active disease as defined by a Vasculitis Disease Activity Index of greater than or equal to 3 or if begun on CYC and glucocorticoid at an outside institution, a history of a Vasculitis Disease Activity Index greater than or equal to 3 at the time of therapy initiation. EXCLUSION CRITERIA: 1. Evidence of active infection which, in the judgment of the investigator, is of greater danger to the patient than the underlying vasculitis. In those instances in which infection cannot be ruled out by gram stain and culture of secretions or collections of fluid in involved organs, it may be necessary to obtain a biopsy of the affected tissue for microbiological and histopathological studies. 2. Patients who are pregnant or who are nursing infants will not be eligible. Fertile women must have a negative pregnancy test within one week prior to study entry and must be using an effective means of birth control. 3. Serological evidence of infection with human immunodeficiency virus, hepatitis C, or a positive hepatitis B surface antigen. A serological determination will be performed within two weeks of beginning study participation. 4. Acute or chronic liver disease, past history of alcohol abuse (greater than 14 oz of 100 proof liquor or equivalent per week), ongoing alcohol use of any volume that cannot be discontinued upon entry into the study. 5. History of CYC- or methotrexate- induced pneumonitis with past treatment. 6. Hypersensitivity to CYC, MPM, or methotrexate. 7. Transitional cell carcinoma of the bladder. 8. Inability to comply with study guidelines. 9. Hemocytopenia: platelet count less than 80,000/mm(3), leukocyte count less than 3,000/mm(3), hematocrit less than 20% (in the absence of gastrointestinal bleeding or hemolytic anemia). |
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Allergy and Infectious Diseases (NIAID) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488-98. — View Citation
Jennette JC. Antineutrophil cytoplasmic autoantibody-associated diseases: a pathologist's perspective. Am J Kidney Dis. 1991 Aug;18(2):164-70. — View Citation
Nölle B, Specks U, Lüdemann J, Rohrbach MS, DeRemee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med. 1989 Jul 1;111(1):28-40. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02498808 -
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?
|
N/A | |
Completed |
NCT01363388 -
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
|
Phase 2 | |
Completed |
NCT00004357 -
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
|
Phase 2 | |
Recruiting |
NCT05263817 -
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
|
Early Phase 1 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Completed |
NCT01947465 -
Immunogenicity and Safety of Vaccinations in Immunocompromised Persons
|
N/A | |
Completed |
NCT02240888 -
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
|
N/A | |
Completed |
NCT03693586 -
Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis
|
||
Completed |
NCT05604482 -
CXCR4-PET/CT for Diagnosing Giant Cell Arteritis
|
N/A | |
Completed |
NCT03765424 -
Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Recruiting |
NCT05383339 -
Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
|
||
Active, not recruiting |
NCT03755245 -
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
|
N/A | |
Recruiting |
NCT05565885 -
Search for BIO Diagnostic and Prognostic Markers in Adult VAScularitis
|
||
Recruiting |
NCT02593565 -
Vasculitis Pregnancy Registry
|
||
Recruiting |
NCT02856243 -
Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis
|
N/A | |
Recruiting |
NCT05628948 -
Vascular Lab Resource (VLR) Biorepository
|
||
Active, not recruiting |
NCT03692416 -
The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children
|
Phase 3 | |
Completed |
NCT05115370 -
Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
|
||
Terminated |
NCT03937856 -
Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases
|
N/A |